Sampling times for monitoring tacrolimus in stable adult liver transplant recipients

Therapeutic Drug Monitoring

Volumn 26, Issue 6, 2004, Pages 593-599

  Dansirikul, Chantaratsamon ^a   Staatz, Christine E ^a   Duffull, Stephen B ^a   Taylor, Paul J ^a,b   Lynch, Stephen V ^a   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Limited sampling strategies; Optimal sampling time; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

TACROLIMUS;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG MONITORING; GRAFT REJECTION; HUMAN; LIQUID CHROMATOGRAPHY; LIVER TRANSPLANTATION; MATHEMATICAL COMPUTING; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; TECHNIQUE;

ADULT; AGED; AREA UNDER CURVE; CONFIDENCE INTERVALS; DRUG MONITORING; FEMALE; GRAFT REJECTION; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; TACROLIMUS; TIME FACTORS;

EID: 9644270245     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200412000-00003     Document Type: Article

References (43)

1. European FK 506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 1994;344:423-428.
2. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 1997;63:977-983.
3. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 1994;331:1110-1115.
4. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation. 1997;64:436-443.
5. Sher LS, Cosenza CA, Michel J, et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. Transplantation. 1997;64:258-263.
6. Pham SM, Kormos RL, Kawai A, et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. Transplant Proc. 1996;28:1002-1004.
7. Asfar S, Atkison P, Ghent C, et al. Small bowel transplantation. A life-saving option for selected patients with intestinal failure. Dig Dis Sci. 1996;41:875-883.
8. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404-430.
9. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit. 1995;17:606-614.
10. Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther. 2002;24:330-350; discussion 329.
11. Ringe B, Braun F, Schutz E, et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation. 2001;71:508-515.
12. Venkataramanan R, Shaw LM, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001;41:542-551.
13. Winkler M, Ringe B, Baumann J, et al. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression. Clin Chem. 1994;40:2247-2253.
14. Backman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation. 1994;57:519-525.
15. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62:920-926.
16. Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. Transplant Proc. 1991;23:3071-3074.
17. Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation. 1996;62:900-905.
18. Bottiger Y, Brattstrom C, Tyden G, et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol. 1999;48:445-448.
19. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant. 2001;16:1905-1909.
20. Kasiske BL, Heim-Duthoy K, Rao KV, et al. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation. 1988;46:716-722.
21. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 1993;54:205-218.
22. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 1999;68:55-62.
23. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999;31:296-298.
24. Braun F, Peters B, Schutz E, et al. Therapeutic drug monitoring of tacrolimus early after liver transplantation. Transplant Proc. 2002;34:1538-1539.
25. Cantarovich M, Fridell J, Barkun J, et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. Transplant Proc. 1998;30:1460-1461.
26. Ku YM, Min DI. An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. Ther Drug Monit. 1998;20:219-223.
27. Ihara H, Shinkuma D, Ichikawa Y, et al. Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients - importance of trough level as a practical indicator. Int J Urol. 1995;2:151-155.
28. Jorgensen K, Povlsen J, Madsen S, et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant. 2002;17:1487-1490.
29. Wong KM, Shek CC, Chau KF, et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis. 2000;35:660-666.
30. Uchida K, Tominaga Y, Haba T, et al. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. Transplant Proc. 2002;34:1736-1737.
31. Pisitkun T, Eiam-Ong S, Chusil S, et al. The roles of C(4) and AUC(0-4) in monitoring of tacrolimus in stable kidney transplant patients. Transplant Proc. 2002;34:3173-3175.
32. Stolk LM, Van Duijnhoven EM, Christiaans MH, et al. Trough levels of tacrolimus. Ther Drug Monit. 2002;24:573.
33. Pedersen AR. Spurious results in therapeutic drug monitoring research. Ther Drug Monit. 2002;24:775-784.
34. David O, Johnston A. Limited sampling strategies. Clin Pharmacokinet. 2000;39:311-313.
35. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm. 1981;9:739-756.
36. Nestorov IA. Sensitivity analysis of pharmacokinetic and pharmacodynamic systems: I. A structural approach to sensitivity analysis of physiologically based pharmacokinetic models. J Pharmacokinet Biopharm. 1999;27:577-596.
37. Staatz CE, Willis C, Taylor PJ, et al. Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transplant. 2003;9:130-137.
38. Taylor PJ, Jones A, Balderson GA, et al. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. Clin Chem. 1996;42:279-285.
39. Taylor PJ, Hogan NS, Lynch SV, et al. Improved therapeutic drug monitoring of tacrolimus (FK506) by tandem mass spectrometry. Clin Chem. 1997;43:2189-2190.
40. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
41. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
42. Efron B, Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation. Am Stat. 1983;37:36-48.
43. Iwasaki K, Shiraga T, Nagase K, et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab Dispos. 1993;21:971-977.